Cargando…
Metallothionein Is Downstream of Nrf2 and Partially Mediates Sulforaphane Prevention of Diabetic Cardiomyopathy
We have reported that sulforaphane (SFN) prevented diabetic cardiomyopathy in both type 1 and type 2 diabetes (T2DM) animal models via the upregulation of nuclear transcription factor erythroid 2–related factor 2 (Nrf2) and metallothionein (MT). In this study, we tested whether SFN protects the hear...
Autores principales: | Gu, Junlian, Cheng, Yanli, Wu, Hao, Kong, Lili, Wang, Shudong, Xu, Zheng, Zhang, Zhiguo, Tan, Yi, Keller, Bradley B., Zhou, Honglan, Wang, Yuehui, Xu, Zhonggao, Cai, Lu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5248986/ https://www.ncbi.nlm.nih.gov/pubmed/27903744 http://dx.doi.org/10.2337/db15-1274 |
Ejemplares similares
-
Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK/NRF2 pathways
por: Wang, Xiang, et al.
Publicado: (2022) -
Sulforaphane prevents angiotensin II‐induced cardiomyopathy by activation of Nrf2 through epigenetic modification
por: Su, Xuling, et al.
Publicado: (2021) -
Methylglyoxal-Induced Endothelial Cell Loss and Inflammation Contribute to the Development of Diabetic Cardiomyopathy
por: Vulesevic, Branka, et al.
Publicado: (2016) -
Partial Inhibition of Insulin Secretion Results in Glucose Intolerance but Not Hyperglucagonemia
por: Ramanathan, Ranjani P., et al.
Publicado: (2011) -
Cannabinoid 1 Receptor Promotes Cardiac Dysfunction, Oxidative Stress, Inflammation, and Fibrosis in Diabetic Cardiomyopathy
por: Rajesh, Mohanraj, et al.
Publicado: (2012)